CSIMarket



Merck and Co Inc   (MRK)
Other Ticker:  
 
 

MRK's Revenue Growth by Quarter and Year

Merck And Co Inc 's Revenue results by quarter and year




MRK Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 12,068.00 12,514.00 11,867.00
III Quarter September - 13,154.00 12,551.00 12,397.00
II Quarter June - 11,402.00 10,872.00 11,760.00
I Quarter March 15,901.00 12,080.00 12,057.00 10,816.00
FY   15,901.00 48,704.00 47,994.00 46,840.00



MRK Revenue first quarter 2022 Y/Y Growth Comment
Merck and Co Inc achieved in the first quarter 2022, above Company average Revenue growth of 31.63% year on year, to $ 15,901.00 millions.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Revenue growth. While Merck And Co Inc ' s Revenue rise of 31.63% ranks overall at the positon no. 403 in the first quarter 2022.




MRK Revenue ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - -3.56 % 5.45 % 7.9 %
III Quarter September - 4.8 % 1.24 % 14.85 %
II Quarter June - 4.87 % -7.55 % 12.37 %
I Quarter March 31.63 % 0.19 % 11.47 % 7.76 %
FY   - 1.48 % 2.46 % 10.75 %

Financial Statements
Merck And Co Inc 's first quarter 2022 Revenue $ 15,901.00 millions MRK's Income Statement
Merck And Co Inc 's first quarter 2021 Revenue $ 12,080.00 millions Quarterly MRK's Income Statement
New: More MRK's historic Revenue Growth >>


MRK Revenue (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - -8.26 % -0.29 % -4.28 %
III Quarter September - 15.37 % 15.44 % 5.42 %
II Quarter June - -5.61 % -9.83 % 8.73 %
I Quarter March 31.76 % -3.47 % 1.6 % -1.65 %
FY (Year on Year)   - 1.48 % 2.46 % 10.75 %




Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #55
Overall #403

Revenue Y/Y Growth Statistics
High Average Low
72.65 % 1.79 % -47.74 %
(Dec 31 2013)   (Sep. 30, 2015)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #55
Overall #403
Revenue Y/Y Growth Statistics
High Average Low
72.65 % 1.79 % -47.74 %
(Dec 31 2013)   (Sep. 30, 2015)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Merck And Co Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
66.84 % 1.88 % -10.73 %
(Dec. 30, 2009)  


MRK's I. Quarter Q/Q Revenue Comment
Merck and Co Inc achieved in the I. Quarter 2022 above company average sequential Revenue jump of 31.76%, to $ 15,901.00 millions, from $12,068.00 millions in the forth quarter.
Merck And Co Inc is impressively improving, not only reporting above normal increase, but also improving rate, Luca Ferrari, market expert mentioned.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Merck And Co Inc 's Revenue growth quarter on quarter, overall rank is 111.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #21
Overall #111
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #21
Overall #111
Revenue Q/Q Growth Statistics
High Average Low
66.84 % 1.88 % -10.73 %
(Dec. 30, 2009)  


MRK's I. Quarter Q/Q Revenue Comment
Merck and Co Inc achieved in the I. Quarter 2022 above company average sequential Revenue jump of 31.76%, to $ 15,901.00 millions, from $12,068.00 millions in the forth quarter.
Merck And Co Inc is going from strength to strength, with recording higher then normal gain, but also increasing speed.

Within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Merck And Co Inc 's Revenue growth quarter on quarter, overall rank is 111.


Merck And Co Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 52,525.00 $ 48,704.00 $ 49,150.00 $ 48,547.00 $ 48,017.00
Y / Y Revenue Growth (TTM) 9.39 % 1.48 % 3.81 % 2.87 % -0.13 %
Year on Year Revenue Growth Overall Ranking # 1277 # 2969 # 2561 # 1814 # 1921
Seqeuential Revenue Change (TTM) 7.85 % -0.91 % 1.24 % 1.1 % 0.05 %
Seq. Revenue Growth (TTM) Overall Ranking # 403 # 1736 # 2696 # 3013 # 2642




Cumulative Revenue growth Comment
Merck And Co Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.39% year on year, to $ 52,525 millions if the fiscal year would have ended in Mar 31 2022.
Merck And Co Inc 's trailing twelve months Revenue growth was higher than company's average 6.99% and higher than 1.48% growth in Dec 31 2021.
But sequential increase was slower at 7.85 % from $48704 millions recorded in the period from Dec 31 2021 to Mar 31 2021.
Yet this was confirmation of positive momentum, as the usual sequential Revenue advancement stands at 1.79%.
The momentum is even higher from twelve months ended Dec 31 2021 showed at 7.85 % increase from $48704 millions in twelve months ending a quarter Dec 31 2021.

In the Healthcare sector 144 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1277, from total ranking in previous quarter at 2969.

Revenue TTM Q/Q Growth Statistics
High Average Low
72.65 %
1.79 %
-47.74 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 145
Overall # 1277

Revenue TTM Y/Y Growth Statistics
High Average Low
88.24 %
6.99 %
-7.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 55
S&P 500 # 403
Cumulative Revenue growth Comment
Merck And Co Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 9.39% year on year, to $ 52,525 millions if the fiscal year would have ended in Mar 31 2022.
Merck And Co Inc 's trailing twelve months Revenue growth was higher than company's average 6.99% and higher than 1.48% growth in Dec 31 2021.
But sequential increase was less at 7.85 % from $48704 millions reported in twelve months ending a quarter Dec 31 2021 Luca Ferrari added on.
In spite of, this was validation of strength, while the average sequential gain is at 1.79%.
The momentum was even stronger sequentially exhibited at 7.85 % jump from $48704 millions in the period from Dec 31 2021 to Mar 31 2021.

In the Healthcare sector 144 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1277, from total ranking in previous quarter at 2969.

Revenue TTM Q/Q Growth Statistics
High Average Low
72.65 %
1.79 %
-47.74 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 23
Healthcare Sector # 145
Overall # 1277

Revenue TTM Y/Y Growth Statistics
High Average Low
88.24 %
6.99 %
-7.58 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 23
Sector # 55
S&P 500 # 403




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MRK's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for MRK's Competitors
Revenue Growth for Merck And Co Inc 's Suppliers
Revenue Growth for MRK's Customers

You may also want to know
MRK's Annual Growth Rates MRK's Profitability Ratios MRK's Asset Turnover Ratio MRK's Dividend Growth
MRK's Roe MRK's Valuation Ratios MRK's Financial Strength Ratios MRK's Dividend Payout Ratio
MRK's Roa MRK's Inventory Turnover Ratio MRK's Growth Rates MRK's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Twist Bioscience Corporation54.23%$ 54.233 millions
American Shared Hospital Services53.10%$ 53.095 millions
Paratek Pharmaceuticals Inc 51.34%$ 51.342 millions
Inari Medical Inc 51.14%$ 51.144 millions
Actinium Pharmaceuticals Inc 51.13%$ 51.125 millions
Apollo Medical Holdings Inc 49.53%$ 49.529 millions
Dermtech Inc 47.31%$ 47.306 millions
Privia Health Group Inc 46.91%$ 46.906 millions
Adapthealth Corp 46.48%$ 46.479 millions
Immucell Corp46.08%$ 46.079 millions
Novabay Pharmaceuticals Inc 45.49%$ 45.490 millions
Apyx Medical Corporation44.63%$ 44.628 millions
Repligen Corp44.50%$ 44.500 millions
Sarepta Therapeutics Inc 43.49%$ 43.489 millions
Harrow Health Inc 43.24%$ 43.236 millions
Harmony Biosciences Holdings inc 42.97%$ 42.965 millions
Catalyst Pharmaceuticals Inc 42.66%$ 42.655 millions
Global Blood Therapeutics Inc 41.28%$ 41.280 millions
Progyny Inc 41.01%$ 41.008 millions
Axonics Inc 40.87%$ 40.866 millions
Tela Bio Inc 40.05%$ 40.054 millions
Bellicum Pharmaceuticals Inc 40.00%$ 40.000 millions
Infinity Pharmaceuticals Inc 39.61%$ 39.615 millions
Merus N v 39.58%$ 39.581 millions
Akoya Biosciences Inc 38.34%$ 38.339 millions
Seelos Therapeutics Inc 36.84%$ 36.842 millions
Dynavax Technologies Corp36.79%$ 36.788 millions
Assertio Holdings inc 36.14%$ 36.138 millions
Precipio inc 34.16%$ 34.156 millions
Iradimed Corp33.46%$ 33.464 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

ZNGY's Profile

Stock Price

ZNGY's Financials

Business Description

Fundamentals

Charts & Quotes

ZNGY's News

Suppliers

ZNGY's Competitors

Customers & Markets

Economic Indicators

ZNGY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071